BioSpace News Archive

Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report its financial results for the fourth quarter and year ended December 31, 2020, after the financial markets close on Thursday March 4, 2021.

BrainsWay Ltd., a global leader in the advanced noninvasive treatment of brain disorders, announced that it intends to offer American Depositary Shares, each representing two ordinary shares, in an underwritten public offering.

BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced the publication by Proceedings of the National Academy of Sciences (PNAS) that describes the design and functionality of therapeutic antibody candidates utilizing BioAtla’s proprietary CAB

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release fourth quarter and full year 2020 financial results after the market closes on Monday, March 1, 2021

AbSci, a pioneering synthetic biology company that unifies biologic drug discovery and development processes, today announced a strategic equity investment by Merck Global Health Innovation Fund (Merck GHI) and potential discovery collaborations with Merck Research Laboratories.

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will present at The Cowen 41st Annual Healthcare Conference on Tuesday, March 2, 2021 at 2:50 p.m. Eastern /11:50 a.m. Pacific.

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will participate at the Cowen 41st Annual Virtual Health Care Conference,

Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, has completed its previously announced acquisition of molecular oncology leader Biotheranostics, Inc. for approximately $230 million.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that its management team will virtually attend the following investor conferences